Details

Autor(en) / Beteiligte

• Ounissi, Marwa
• Rodrigues, Christelle
• Bienayme, Hugues
• Duhamel, Paul
• Pons, Gérard
• Dulac, Olivier
• Nabbout, Rima
• Chiron, Catherine
• Jullien, Vincent

Titel

Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data

Ist Teil von

• Journal of clinical pharmacology, 2019-02, Vol.59 (2), p.177-188

Ort / Verlag

England: American College of Clinical Pharmacology

Erscheinungsjahr

2019

Beschreibungen/Notizen

• Vigabatrin is an antiepileptic drug indicated as monotherapy in infantile spasms. However, the pharmacokinetic profile of this compound in infants and young children is still poorly understood, as is the minimal effective dose, critical information given the risk of exposure‐related retinal toxicity with vigabatrin. A reasonable approach to determining this minimal dose would be to identify the lowest dose providing a low risk of exposure overlap with the 36‐mg/kg dose, which is the highest dose associated with an increased risk for treatment failure, based on randomized dose‐ranging data. A population pharmacokinetic model was consequently developed from 28 children (aged 0.4‐5.7 years) for the active S(+)‐enantiomer, using Monolix software. In parallel, a population model was developed from published adult data and scaled to children using theoretical allometry and maturation of the renal function. A one‐compartment model with zero‐order absorption and first‐order elimination described the pediatric data. Mean population estimates (percentage interindividual variability) for the apparent clearance, apparent distribution volume, and absorption duration were 2.36 L/h (24.5%), 17 L (38%), and 0.682 hours, respectively. Apparent clearance and apparent distribution volume were related to body weight by empirical allometric equations. Monte Carlo simulations evidenced that a daily dose of 80 mg/kg should minimize exposure overlap with the 36‐mg/kg dose. Similar results were obtained for the adult model scaled to children. Consequently, a minimal effective dose of 80 mg/kg/day could be considered for patients with infantile spasms.